Subscribe
shutterstock_1396957739_pavel_kapysh
Pavel Kapysh / Shutterstock.com
4 February 2020AmericasSarah Morgan

Idenix $2.5bn ruling will impede innovation, says Amgen

Pharmaceutical company Amgen has asked a full US Court of Appeals for the Federal Circuit to review the overturning of a record $2.5 billion verdict against Gilead Sciences.

Already registered?

Login to your account

To request a FREE 2-week trial subscription, please signup.
NOTE - this can take up to 48hrs to be approved.

Two Weeks Free Trial

For multi-user price options, or to check if your company has an existing subscription that we can add you to for FREE, please email Adrian Tapping at atapping@newtonmedia.co.uk


More on this story

Americas
Gilead escapes enhanced damages in $2.5bn Idenix verdict
25 September 2017   Biopharmaceutical company Gilead has escaped a finding of enhanced damages in its patent dispute with Idenix Pharmaceuticals, a subsidiary of Merck.
Americas
MSD petitions SCOTUS over $2.5bn patent verdict
28 September 2020   MSD subsidiary Idenix has urged the US Supreme Court to review the overturning of a record $2.5 billion verdict against Gilead Sciences.
Big Pharma
Fed Circuit refuses Amgen unit appeal in win for Sanofi
15 October 2020   The US Court of Appeals for the Federal Circuit has dismissed Immunex’s appeal against a decision invalidating its patent on treating inflammatory disorders.


Editor's picks

Americas
Trump’s return sparks calls for pro-patent agenda
5 December 2024

Editor's picks

Americas
Trump’s return sparks calls for pro-patent agenda
5 December 2024
Americas
Comparing life sciences IP in Brazil and the US
28 November 2024
Americas
UPC bans Meril Life Sciences from selling infringing heart valve
19 November 2024
Americas
Amgen set for ‘at-risk’ launch of blockbuster eye drug biosimilar
24 October 2024
Americas
Big Pharma counsel embrace AI but data and legal risks loom
24 October 2024
Asia
President Xi sends message to AIPPI’s World Congress
22 October 2024

More on this story

Americas
Gilead escapes enhanced damages in $2.5bn Idenix verdict
25 September 2017   Biopharmaceutical company Gilead has escaped a finding of enhanced damages in its patent dispute with Idenix Pharmaceuticals, a subsidiary of Merck.
Americas
MSD petitions SCOTUS over $2.5bn patent verdict
28 September 2020   MSD subsidiary Idenix has urged the US Supreme Court to review the overturning of a record $2.5 billion verdict against Gilead Sciences.
Big Pharma
Fed Circuit refuses Amgen unit appeal in win for Sanofi
15 October 2020   The US Court of Appeals for the Federal Circuit has dismissed Immunex’s appeal against a decision invalidating its patent on treating inflammatory disorders.

More on this story

Americas
Gilead escapes enhanced damages in $2.5bn Idenix verdict
25 September 2017   Biopharmaceutical company Gilead has escaped a finding of enhanced damages in its patent dispute with Idenix Pharmaceuticals, a subsidiary of Merck.
Americas
MSD petitions SCOTUS over $2.5bn patent verdict
28 September 2020   MSD subsidiary Idenix has urged the US Supreme Court to review the overturning of a record $2.5 billion verdict against Gilead Sciences.
Big Pharma
Fed Circuit refuses Amgen unit appeal in win for Sanofi
15 October 2020   The US Court of Appeals for the Federal Circuit has dismissed Immunex’s appeal against a decision invalidating its patent on treating inflammatory disorders.

More features

Fed Circ orders Teva to delist five patents from Orange Book
Sarepta wins $115M in patent dispute over muscular dystrophy drug
Novartis shields eye-drop patent at European Patent Office
CREATES Act unfairly tips the scales to generics
LSPN launches its first-ever US awards to celebrate life sciences leaders
Pharma giants seek closure on COVID-19 vaccine rows
How Inhibrx defended a $450m damages suit
Foley & Lardner adds litigation and transaction expert in New York